glp 1 and kidney GLP-1 agonists in the treatment of chronic disease in type 2 diabetes obesity Proposed mechanism of GLP-1 RA
Description
Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., and Stein P
Secondary Tool: Use #FibroScan (#VCTE) for patients with indeterminate FIB-4 or high clinical suspicion
Priv, F
Short-acting GLP-1 Agonists remain relevant for specific postprandial glucose management
95% CI, 0.52-0.98)
